Breaking News Instant updates and real-time market news.

GPRO

GoPro

$14.07

0.47 (3.46%)

, COTY

Coty

$23.39

0.05 (0.21%)

08:45
10/18/16
10/18
08:45
10/18/16
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: GoPro (GPRO) 52.12% +1.39, Coty (COTY) 1.49% +1.24, Twilio (TWLO) 95.58% +0.40, Golar LNG (GLNG) 1.15% +0.28, Imperva (IMPV) 0.86% +0.26, Vodafone (VOD) 0.72% +0.17, Mylan (MYL) 0.76% +0.17, Fitbit (FIT) 4.18% +0.15, Potash (POT) 3.44% +0.14, and Clovis (CLVS) 1.36% +0.14.

GPRO

GoPro

$14.07

0.47 (3.46%)

COTY

Coty

$23.39

0.05 (0.21%)

TWLO

Twilio

$44.45

-1.66 (-3.60%)

GLNG

Golar LNG

$22.85

0.4 (1.78%)

IMPV

Imperva

$46.90

-2.13 (-4.34%)

VOD

Vodafone

$27.81

0.01 (0.04%)

MYL

Mylan

$36.44

-0.05 (-0.14%)

FIT

Fitbit

POT

Potash

$15.81

-0.19 (-1.19%)

CLVS

Clovis

$31.85

0.04 (0.13%)

  • 02

    Nov

  • 03

    Nov

  • 03

    Nov

  • 03

    Nov

  • 06

    Nov

  • 08

    Nov

  • 09

    Nov

  • 09

    Nov

  • 14

    Nov

  • 16

    Nov

  • 08

    Dec

  • 12

    Dec

  • 23

    Feb

  • 28

    Mar

GPRO GoPro
$14.07

0.47 (3.46%)

10/17/16
CLVD
10/17/16
NO CHANGE
CLVD
GoPro Hero 5 sell through better than targets, says Cleveland Research
Cleveland Research said initial GoPro Hero 5 sell through is better than targets as partner fulfillment levels appear to be 50-75% of orders. The firm's analyst said supply chain discussions are slightly better versus previous discussions for FY16 camera and drone volumes.
10/13/16
JPMS
10/13/16
NO CHANGE
JPMS
Overweight
JPMorgan says buy GoPro on today's weakness
JPMorgan analyst Paul Coster views today's weakness in shares of GoPro (GPRO) as a buying opportunity. While GoPro is not shipping Hero 5 via the Amazon (AMZN) channel today, Amazon has been consistently a top five channel partner for the action camera maker, Coster tells investors in a research note. He expects Amazon shipments to resume by month end and points out the hiatus does not apply to international Amazon sales. The one month impact would be 30,000 Hero 5 units through this channel, or less than $10M in GoPro sales, Coster estimates. He calls the decision to halt shipments to Amazon voluntary and believes the company has alternative distribution channels for the new product. Coster has an Overweight rating on GoPro. The shares are down 22c to $14.08 after Piper Jaffray this morning highlighted that Hero shipments to Amazon have stopped.
10/13/16
JPMS
10/13/16
NO CHANGE
JPMS
GoPro selloff brings buying opportunity, says JPMorgan
10/13/16
PIPR
10/13/16
NO CHANGE
Target $9
PIPR
Underweight
GoPro currently not shipping to Amazon, says Piper Jaffray
Piper Jaffray analyst Erinn Murphy says she uncovered that GoPro (GPRO) is not currently selling to Amazon (AMZN), at least domestically, in a change that occurred over the last three weeks. In a follow-up research note after speaking to management, Murphy clarified that the pause in shipping to Amazon is planned to be temporary. GoPro plans to resume shipping to Amazon at the end of October, Murphy adds. The action camera maker has been shipping to Best Buy (BBY), other partners and its own GoPro.com channel in the meantime, she points out. Nonetheless, the analyst believes the disruption at Amazon was not contemplated in guidance. Murphy is "incrementally concerned" on GoPro's ability to reach its second half of 2016 guidance. The analyst reiterates an Underweight rating on the shares with a $9 price target. The stock closed yesterday down 72c to $14.30.
COTY Coty
$23.39

0.05 (0.21%)

09/29/16
RILY
09/29/16
UPGRADE
Target $23.25
RILY
Neutral
Coty upgraded to Neutral from Sell at B. Riley
B. Riley analyst Linda Bolton Weiser upgraded Coty to Neutral and raised her price target for the shares to $23.25 from $21.50. The stock is closer to fair value following the 20% pullback, Weiser tells investors in a research note.
10/03/16
BOFA
10/03/16
UPGRADE
Target $28
BOFA
Buy
Coty upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Olivia Tong upgraded Coty to Buy with a $28 price target citing valuation. The analyst believes Coty is at the beginning of a potential transformation with the pending closure of the P&G Beauty deal this week that could bring increased scale as well as a more targeted operational structure.
10/03/16
PIPR
10/03/16
NO CHANGE
PIPR
Chinese tax changes modestly positive for cosmetics makers, says Piper Jaffray
Piper Jaffray analyst Stephanie Wissink noted that the Chinese Ministry of Finance has reduced or eliminated the consumption tax on all cosmetic products as of October 1 to stimulate demand and growth, which she views as a modest positive for Estee Lauder (EL), Avon Products (AVP) and Coty (COTY). Of the three, Estee Lauder has the highest exposure to China, which makes up about 10% of its annual revenues, Wissink added.
10/03/16
10/03/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dow Chemical (DOW) and DuPont (DD) were upgraded to Buy from Neutral at Citi with analyst P.J. Juvekar citing he opportunity presented by the proposed merger. 2. Freeport McMoRan (FCX), Barrick Gold (ABX), and Pan American Silver (PAAS) were upgraded to Buy from Hold at Deutsche Bank. 3. LogMeln (LOGM) upgraded to Overweight from Equal Weight at Barclays with analyst Raimo Lenschow saying the pending merger with Citrix's (CTXS) divested GoTo assets creates a "great new opportunity." 4. Halliburton (HAL) upgraded to Buy from Hold at Societe General. 5. Coty (COTY) upgraded to Buy from Neutral at BofA/Merrill with analyst Olivia Tong saying she believes Coty is at the beginning of a potential transformation with the pending closure of the P&G Beauty deal this week that could bring increased scale as well as a more targeted operational structure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TWLO Twilio
$44.45

-1.66 (-3.60%)

07/18/16
JPMS
07/18/16
INITIATION
Target $39
JPMS
Neutral
Twilio initiated with a Neutral at JPMorgan
JPMorgan analyst Mark Murphy started Twilio with a Neutral rating and $39 price target.
07/18/16
07/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Twilio (TWLO) initiated with a Neutral at Goldman, an Outperform at William Blair, a Hold at Canaccord, a Sector Weight at Pacific Crest, a Market Perform at JMP Securities, and with a Neutral at JPMorgan. 2. Selecta Biosciences (SELB) initiated with a Buy at UBS, a Buy at Stifel, a Buy at Canaccord, and a Buy at Needham. 3. China Mobile (CHL) and China Telecom (CHA) assumed with a Buy at Jefferies. 4. NetEase (NTES) initiated with a Buy at Brean Capital. 5. Sysco (SYY) reinstated with a Hold at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/25/16
ARGS
08/25/16
INITIATION
ARGS
Hold
Twilio initiated with a Hold at Argus
Argus analysts Stephen Biggar and Mike Jaffe say that Twilio's opportunists should increase significantly going forward, but they predict that it will report losses "for several more quarters." The analysts say that the stock appears to be "fully valued" at current levels.
08/25/16
08/25/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cree (CREE) initiated with a Buy at Roth Capital. 2. Reynolds American (RAI) initiated with a Neutral at UBS. 3. Twilio (TWLO) initiated with a Hold at Argus. 4. Phillips 66 Partners (PSXP) initiated with a Neutral at Goldman. 5. WD-40 (WDFC) initiated with a Hold at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GLNG Golar LNG
$22.85

0.4 (1.78%)

08/01/16
08/01/16
UPGRADE
Target $21

Buy
Golar LNG upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Ken Hoexter upgraded Golar LNG to Buy and raised its price target to $21 from $19. The analyst believes negative news of low LNG rates, delayed new terminals, and potential financing gap are reflected in shares.
08/01/16
08/01/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Golar LNG (GLNG) upgraded to Buy from Neutral at BofA/Merrill with analyst Ken Hoexter saying he believes negative news of low LNG rates, delayed new terminals, and potential financing gap are reflected in shares. 2. Coach (COH) upgraded to Positive from Mixed at OTR Global following checks that indicate steady progress by store managers, more appealing offerings, new open-to-the-public Mother's Day sale at full-price Coach stores and tight wholesale distribution. 3. Harley-Davidson (HOG) upgraded to Outperform from Market Perform at BMO Capital with analyst Gerrick Johnson saying the stock provides a good contrarian trading opportunity, given the highly negative sentiment towards it. Over the longer term, the analyst thinks that the company's accelerated development of new products will beat fruit. 4. Dollar Tree upgraded to Buy from Hold at Deutsche Bank with analyst Paul Trussell saying the Family Dollar acquisition will provide "more upside opportunities." 5. Houghton Mifflin (HMHC) upgraded to Buy from Neutral at Goldman with analyst Andre Benjamin saying the shares can rally on both positive estimate revisions and multiple expansion after underperforming year-to-date. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/07/16
MSCO
09/07/16
NO CHANGE
Target $30
MSCO
Overweight
Morgan Stanley has increased confidence in Golar LNG growth potential
Morgan Stanley analyst Fotis Giannakoulis has increased confidence in Golar LNG's growth potential following the creation of two new joint ventures of Golar Power with Stonepeak and OneFLNG with Schlumberger and the positive commentary on Ophir's Fortuna FLNG. The analyst reiterates his Overweight rating and increased its price target to $30 from $29 on Golar LNG shares.
10/03/16
ABNA
10/03/16
UPGRADE
ABNA
Hold
Golar LNG upgraded to Hold from Sell at ABN Amro
IMPV Imperva
$46.90

-2.13 (-4.34%)

10/06/16
DADA
10/06/16
DOWNGRADE
DADA
Neutral
Imperva downgraded on valuation at DA Davidson
As noted earlier, DA Davidson downgraded Imperva to Neutral from Buy. Analyst Jack Andrews downgraded the stock based on valuation. He thinks that a number of strategic and financial entities could be interested in buying Imperva, and he believes that the company will probably be sold "over the next few months." However, the analyst thinks that the company may not be bought for a price that is significantly higher than its current valuation. Target remains $55.
10/06/16
DADA
10/06/16
DOWNGRADE
DADA
Neutral
Imperva downgraded to Neutral from Buy at DA Davidson
10/03/16
BTIG
10/03/16
DOWNGRADE
BTIG
Neutral
Imperva downgraded to Neutral from Buy at BTIG
BTIG analyst Joel Fishbein downgraded Imperva to Neutral saying valuation reflects a potential acquisition of the company.
09/26/16
NOMU
09/26/16
DOWNGRADE
NOMU
Neutral
Imperva downgraded to Neutral from Buy at Nomura
Nomura downgraded Imperva to Neutral with a $50 price target saying Friday's share strength reflects a potential acquisition of the company.
VOD Vodafone
$27.81

0.01 (0.04%)

09/20/16
ARGS
09/20/16
INITIATION
ARGS
Hold
Vodafone initiated with a Hold at Argus
Argus analysts Stephen Biggar and Mike Jaffe say that Vodafone's capital investments and its efforts to expand its offerings should make it more profitable "over time." However, the analysts think that these growth prospects are already reflected in the stock.
07/12/16
SBSH
07/12/16
DOWNGRADE
SBSH
Neutral
Vodafone downgraded to Neutral from Buy at Citi
Citi downgraded Vodafone to Neutral citing the recent outperformance of shares and potential risk from October's constitutional referendum in Italy.
06/13/16
06/13/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. SAP (SAP) downgraded to Underperform from Hold at Jefferies with analyst Milan Radia saying the company's "journey from licence centricity to subscription will remain prone to shorter-term growth rate inconsistencies." 2. Vodafone (VOD) downgraded to Neutral from Outperform at Macquarie with the firm saying the company faces structural challenges and either needs to pursue Mergers & Acquisitions or continually spend more on networks given competition from incumbents and challengers. 3. Waste Connections (WCN) downgraded to Hold from Buy at TD Securities with analyst Damir Gunja citing valuation and maintained a $78 price target on the stock. 4. Atwood Oceanics (ATW) downgraded to Hold from Buy at Johnson Rice with the firm saying recent liquidity catalysts are now largely reflective in shares, while out year contract coverage concerns remain and multiples currently stand at a solid premium to peer averages on our out-year forecast. 5. Baidu (BIDU) downgraded to Neutral from Buy at Citi with analyst Alicia Yap citing concerns about near-term revenue. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/13/16
MACQ
06/13/16
DOWNGRADE
MACQ
Neutral
Vodafone downgraded to Neutral from Outperform at Macquarie
Macquarie downgraded Vodafone to Neutral saying the company faces structural challenges and either needs to pursue M&A or continually spend more on networks given competition from incumbents and challengers.
MYL Mylan
$36.44

-0.05 (-0.14%)

10/10/16
WELS
10/10/16
NO CHANGE
WELS
Mylan settlement does not end EpiPen issue, says Wells Fargo
In a research note titled "Forget After Hrs. Quarterbacking - It is Not Back to Normal," Wells Fargo analyst David Maris says Mylan questions still remain after the company's lowered 2016 outlook and $465M Department of Justice settlement. One of Mylan's earnings levers, EpiPen pricing, is now off the table going forward, Maris tells investors in a research note. The analyst disagrees with investors that think the settlement puts the EpiPen pricing issue largely behind the company. The deal with the DOJ addresses only the Centers for Medicare and Medicaid Services portion of the issue, it does nothing to answer the original issue of EpiPen pricing and consumers, Maris contends. He points out that Mylan also disclosed in Friday's regulatory filing, but not in its press release, an SEC investigation by the Division of Enforcement. Maris says he's "not too excited" and doesn't gauge how good the news is by the after-hours share rally of 10%. He believes Mylan is "not back to normal" and keeps a Market Perform rating on the stock with a $43-$45 price target range. The shares are up 12% in pre-market trading to $40.35. Raymond James this morning upgraded Mylan to Strong Buy.
10/10/16
10/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Strong Buy from Market Perform at Raymond James with Elliot WIlbur saying the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. 2. Under Armour (UA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales re-acceleration over the next 12-18 months. 3. Deere (DE) and AGCO (AGCO) were upgraded to Outperform from Market Perform at Wells Fargo. 4. Dow Chemical (DOW) upgraded to Buy from Neutral at UBS with analyst John Roberts saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." 5. Exelixis (EXEL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying the data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/16
RAJA
10/10/16
UPGRADE
Target $57
RAJA
Strong Buy
Mylan upgraded to Strong Buy on EpiPen settlement at Raymond James
As previously reported, Raymond James upgraded Mylan two notches to Strong Buy from Market Perform and established a $57 price target. Analyst Elliot WIlbur said the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. With depressed absolute and relative valuation levels, Wilber sees favorable risk/reward scenarios even in a more tempered earnings growth environment.
10/10/16
JPMS
10/10/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan settlement, updated guidance a positive, says JPMorgan
JPMorgan analyst Chris Schott views Mylan's $465M settlement with the Department of Justice relating to the potential misclassification of Epipen in the Medicaid Drug Rebate Program as well as its updated 2016 guidance as a positive. The news "removes litigation overhang at a reasonable cost and highlights the diversification of the base business and inexpensive valuation," Schott tells investors in a research note. He keeps an Overweight rating on Mylan with a $52 price target.
FIT Fitbit

09/29/16
MZHO
09/29/16
NO CHANGE
MZHO
Fitbit shares defended at Mizuho
09/29/16
MZHO
09/29/16
NO CHANGE
MZHO
Fitbit Charge 2 checks remain strong, pullback unwarranted, says Mizuho
Mizuho's checks indicate Fitbit's Charge 2 sell through remains strong with favorable reviews, despite investor concerns. The firm's analyst views the pullback in Fitbit shares as unwarranted, especially since Q3 guidance assume minimal unit sales, and expects the Charge 2 to compete well and serve as a catalyst for Holiday season into Spring 2017. Mizuho continues to believe in Fitbit's long-term opportunity to maintain dominant share with in the increasingly growing global market for wearables while pursing opportunities in the healthcare industry.
10/07/16
CLVD
10/07/16
NO CHANGE
CLVD
Cleveland Research is cautious on Fitbit heading into Q4 and Q1 2027
Cleveland Research is cautious on Fitbit heading into Q4 and Q1 2027 saying new product uptake is muted and is concerned about inventory levels.
10/17/16
LBOW
10/17/16
NO CHANGE
LBOW
Buy
Fitbit Charge 2 launch has met expectations in U.S., says Longbow
Longbow analyst Joe Wittine said his channel checks indicate that the launch of Fitbit's (FIT) Charge 2 device has met "conservative" initial expectations in the U.S. and is exceeding expectations in Europe, disputing "a couple calls to the contrary." Additionally, his contacts see no reason to doubt Q4 holiday demand for Fitbit, noted Wittine, who keeps a Buy rating on the stock. The analyst also noted that his checks indicate Garmin's (GRMN) Fitness sales are growing in the low-20% range, providing potential for upside, though he keeps a Neutral rating on its shares.
POT Potash
$15.81

-0.19 (-1.19%)

09/26/16
09/26/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Hold from Reduce at HSBC. 2. Potash (POT) upgraded to Positive from Neutral at Susquehanna with analyst Don Carson citing expected benefits from the company's proposed merger with Agrium (AGU), which he sees as having relatively low antitrust risk compared to the other mega-mergers being pursued in the Ag space. 3. Oshkosh (OSK) upgraded to Overweight from Neutral at JPMorgan and to Neutral from Underperform at Credit Suisse. 4. Marriott (MAR) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Thomas Allen citing strong unit growth. 5. NetApp (NTAP) upgraded to Buy from Hold at Cross Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/26/16
SUSQ
09/26/16
UPGRADE
Target $21
SUSQ
Positive
Potash upgraded to Positive at Susquehanna
As previously reported, Susquehanna analyst Don Carson upgraded Potash (POT) to Positive from Neutral, citing expected benefits from the company's proposed merger with Agrium (AGU), which he sees as having relatively low antitrust risk compared to the other mega-mergers being pursued in the Ag space. The firm, which also has a Positive rating for Agrium shares, raised its price target on Potash to $21 from $16 increased its price target on Agrium to $116 from $109.
10/10/16
RBCM
10/10/16
UPGRADE
RBCM
Outperform
Potash upgraded on merger at RBC Capital
As noted on Friday, RBC Capital upgraded Potash (POT) to Outperform from Sector Perform. RBC Capital analyst Andrew Wong says that the estimated synergies of the Agrium (AGU)/Potash merger are "compelling." Wong calls the synergies "ambitious but achievable," and adds that the strategic benefits of the deal are "just as important as synergies." He thinks that the benefits of the deal "outweigh potential risks related to changing potash exposure." Target to $19 from $15.
10/07/16
RBCM
10/07/16
UPGRADE
RBCM
Outperform
Potash upgraded to Outperform from Sector Perform at RBC Capital
CLVS Clovis
$31.85

0.04 (0.13%)

10/07/16
RHCO
10/07/16
NO CHANGE
Target $50
RHCO
Buy
Clovis selloff a buying opportunity, says SunTrust
SunTrust analyst Peter Lawson views today's selloff in shares of Clovis Oncology as a buying opportunity, saying today's concern "seems like noise." The analyst has a Buy rating on the stock with a $50 price target. Clovis is down 13%, or $4.64, to $31.13 but is well off the day's lows.
10/07/16
PIPR
10/07/16
NO CHANGE
PIPR
Neutral
Piper still sees Clovis' rucaparib getting broader indication than Lynparza
Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $42
PIPR
Neutral
Clovis price target raised to $42 from $14 at Piper Jaffray
Piper Jaffray analyst Steven Breazzano raised his price target for Clovis Oncology (CLVS) to $42 after taking a "comprehensive look" at the PARP inhibitor landscape in ovarian cancer and beyond. The company's PARP inhibitor rucaparib has demonstrated an active profile in ovarian cancer and all signs point to an approval in the 3L+ setting early next year, Breazzano tells investors in a research note. The analyst, however, believes the ultimate key is success in the earlier maintenance setting, and he thinks the race may still be Tesaro's (TSRO) niraparib's to lose. Breazzano keeps a Neutral rating on Clovis.
09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).

TODAY'S FREE FLY STORIES

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

CELG

Celgene

$117.63

-1.24 (-1.04%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.